CliffBio
small molecule

VYALEV

FOSCARBIDOPA; FOSLEVODOPA

Loss of exclusivityJune 2040latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameVYALEV
Active ingredientFOSCARBIDOPA; FOSLEVODOPA
Strength120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalOctober 2024
Marketing statusRX

Listed patents

PatentExpiresType
12251365June 2040use U-4030
9446059October 2035substance, product
10174061October 2035product
10730895October 2035substance

Regulatory exclusivity

CodeExpires
NPOctober 2027

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.